In studies that included patients independent of uterine cancer histological types, both HER2 expression and amplification were significantly correlated with features of aggressive disease, such as higher stage, positive lymph node status, and greater than 50% myometrial invasion [32]. The gene discussed is ERBB2; the disease is uterine cancer.